Kyverna Therapeutics
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥11-50
📍Emeryville
Kyverna Therapeutics
About Kyverna Therapeutics
Kyverna Technologies are bringing curative living medicines to life to free patients from the siege of autoimmune disease.
Kyverna Therapeutics news and updates
Kyverna Therapeutics, Inc. hired Tom Van Blarcom as executive director, head of Protein Engineering and Research Operation on Jul 26th 22'.
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has appointed Tom Van Blarcom, Ph.D., as senior vice president and head of Research.
Aug 25, 2022 | contractpharma.comGilead Sciences, Inc. invests into Kyverna Therapeutics, Inc.
Meanwhile, Gilead Sciences ( GILD ) invested in an early fundraising round for Kyverna Therapeutics.
Aug 29, 2022 | thestreet.comKyverna Therapeutics, Inc. launches KYV-101
“Georg’s pioneering work recently demonstrated that CD19 CAR T-cell therapy can induce rapid and prolonged remission of B-cell driven autoimmune diseases such as severe refractory lupus.1,2 His experience with this transformative approach will be essential to help Kyverna Therapeutics, Inc. successfully introduce KYV-101, a novel CD19 CAR T-cell therapy for the treatment of lupus nephritis, in the clinic in Q4 2022.
Aug 22, 2022 | kyvernatx.com